Patents by Inventor Syed Raza ALI

Syed Raza ALI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240228964
    Abstract: Memory-like cytokine enhanced NK (M-CENK) cells have superior cytotoxicity and can be generated/expanded from a single batch of mononuclear cells to in sufficient quantities to so form a cell-based therapeutic suitable for infusion. Advantageously, the M-CENK cells can be cryopreserved and thawed without compromising viability and cytotoxicity.
    Type: Application
    Filed: March 1, 2022
    Publication date: July 11, 2024
    Applicants: ImmunityBio, Inc., ImmunityBio, Inc.
    Inventors: Manju Saxena, Syed Raza Ali, Greg Anderson, Patrick Soon-Shiong
  • Publication number: 20240132844
    Abstract: Memory-like cytokine enhanced NK (M-CENK) cells have superior cytotoxicity and can be generated/expanded from a single batch of mononuclear cells to in sufficient quantities to so form a cell-based therapeutic suitable for infusion. Advantageously, the M-CENK cells can be cryopreserved and thawed without compromising viability and cytotoxicity.
    Type: Application
    Filed: March 1, 2022
    Publication date: April 25, 2024
    Applicants: ImmunityBio, Inc., ImmunityBio, Inc.
    Inventors: Manju Saxena, Syed Raza Ali, Greg Anderson, Patrick Soon-Shiong
  • Publication number: 20230381313
    Abstract: Cells and cell-based therapeutic compositions and methods are presented in which the cells are CD16+CD57+NK-92MI cells that natively express CD16 and CD57 and that exhibit IL-2 independent growth.
    Type: Application
    Filed: May 10, 2023
    Publication date: November 30, 2023
    Applicant: ImmunityBio, Inc.
    Inventors: Scotty Cadet, Syed Raza Ali, Manju Saxena, Barry J. Simon
  • Publication number: 20220265716
    Abstract: Provided herein are pharmaceutical compositions, comprising a pharmaceutically acceptable carrier and therapeutically effective amounts of high affinity Natural Killer (haNK) cells and a therapeutic antibody in the form of a combined preparation. Also provided herein are methods for treating cancer by using the pharmaceutical composition comprising the haNK cells and the therapeutic antibody.
    Type: Application
    Filed: July 27, 2020
    Publication date: August 25, 2022
    Inventors: Barry Simon, Manju Saxena, Syed Raza Ali, Joseph Thibault
  • Publication number: 20210363484
    Abstract: Provided herein are methods of culturing NK-92® cells using the growth media containing a non-ionic surfactant such that the cell culture have reduced clumping as compared to control NK-92® cells that have been cultures in a control medium lacking the non-ionic surfactant. The growth medium comprises 0.025 to 0.9% of a non-ionic surfactant, e.g., Poloxamer 188.
    Type: Application
    Filed: May 21, 2019
    Publication date: November 25, 2021
    Inventors: Shannyn BESSETTE, Diemchi NGUYEN, Syed Raza ALI, Manju SAXENA
  • Publication number: 20210267190
    Abstract: Provided herein are methods and medium compositions for cryopreserving NK-92® cells.
    Type: Application
    Filed: July 9, 2019
    Publication date: September 2, 2021
    Inventors: Shannyn BESSETTE, Syed Raza ALI, Manju SAXENA
  • Publication number: 20210040451
    Abstract: Provided herein are methods of harvesting NK-92® cells comprising collecting NK-92® cells from a cell culture and washing the collected NK-92® cells in a buffer comprising 1%-5% albumin.
    Type: Application
    Filed: January 30, 2019
    Publication date: February 11, 2021
    Inventors: Shannyn BESSETTE, Syed Raza ALI, Manju SAXENA